Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2026)

Crinetics Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 1.35% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 1.35% YoY), while the FY2025 annual figure was -$1.0 billion, up 24.09% from the prior year.
• Enterprise Value was -$1.3 billion for Q1 2026 at Crinetics Pharmaceuticals, down from -$1.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$34.6 million in Q4 2022 to a low of -$1.4 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$672.7 million across 5 years, with a median of -$862.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 86.91% in 2023, then plunged 2052.27% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$34.6 million in 2022, then sank by 1512.41% to -$558.6 million in 2023, then slumped by 142.42% to -$1.4 billion in 2024, then advanced by 24.09% to -$1.0 billion in 2025, then retreated by 25.63% to -$1.3 billion in 2026.
• The last three Enterprise Value figures came in at -$1.3 billion (Q1 2026), -$1.0 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.